Friday, February 5th, 2016 - NewsMaker

Sale Enables Greater Focus on Core Business of Regenerative Medicine and Wound Care

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- Feb 05, 2016 -- Avita Medical Limited (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, has completed the sale of its respiratory business to Medical Developments International Limited (ASX: MVP) for $2.47m.

The strategic divestment of the respiratory business will allow Avita to concentrate exclusively on its core business of regenerative medicine and wound care.

Avita Medical's respiratory business included two products, Breath-A-Tech® and Funhaler®, which are both asthma spacers aimed at optimizing the use of medicinal puffers. The products are marketed in pharmacies throughout Australia.

The transaction was comprised of $2.029m cash, plus 117,894 new MVP shares escrowed for 6 months valued at $0.44m at the time of closing. The final price was adjusted to accommodate for such elements as receivables and a stock valuation.

The sale represents the second input of non-dilutive capital Avita has received in recent months, following last September's conclusion of a deal worth up to USD $54.9m from the US federal disaster preparedness agency BARDA. The company is already invoicing BARDA under a program to support the completion of Avita's FDA approval and its entry to the US market.

"With the sale of the respiratory business, we now have complete focus on our most valuable asset -- our ReCell® autologous cell harvesting technology," said Avita Medical's CEO, Adam Kelliher. "The sale proceeds will enable us to focus on our core commercialisation and clinical goals, such as completing our ReCell® FDA approval trial, currently underway in the US."

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin, yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, pending completion of the FDA approval trial, ReCell® is an investigational device limited by federal law to investigational use. To learn more, visit


Avita Medical Ltd 
Adam Kelliher 
Chief Executive Officer 
Phone: +44 (0) 1763 269 770 
[email protected] 

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
[email protected] 

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
[email protected] 

Instinctif Partners 
Gemma Howe/Sue Charles 
Phone +44 (0)20 7866 7860 
[email protected] 

The Ruth Group
Lee Roth 
Investor Relations
Kirsten Thomas
Phone: +1 (646) 536-7012 / +1 (508) 280-6592
[email protected] / [email protected] 

Monsoon Communications
Dean Felton
Investor Relations / PR
Phone: +61 3 9620 3333
[email protected] 

Contact Profile


NewsMaker is an Australian Press Release Distribution and Social Media Marketing service founded in 2004. The company today represents over 22,000 brands who seek to share their content with journalists, bloggers and the community.

Newsmaker Editors
P: +61 414 69 70 71


Avita Medical Completes Sale Respiratory Business $247m



More Formats